Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LXRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sotagliflozin (LX4211) FDA approved May 2023 · Inpefa |
Type 1 Diabetes (T1D) | Phase 3 · NCT07211802 | Not yet recruiting |
| Telotristat Etiprate | Carcinoid Syndrome | Phase 3 · NCT02026063 | Completed |
| Metformin | Type 2 Diabetes Mellitus | Phase 3 · NCT03066830 | Completed |
| Sulfonylurea Antidiabetic Agent | Type 2 Diabetes Mellitus | Phase 3 · NCT03066830 | Completed |
| Oral Antidiabetes Drugs (OADs) | Type 2 Diabetes Mellitus | Phase 3 · NCT03285594 | Completed |
| LX9211 | Diabetic Peripheral Neuropathic Pain | Phase 2 · NCT06203002 | Completed |
| Nab-paclitaxel | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Phase 2 · NCT03910387 | Completed |
| Octreotide LAR Depot | Carcinoid Syndrome | Phase 2 · NCT00853047 | Completed |
| Volagidemab | Type 1 Diabetes | Phase 1/2 · NCT05696366 | Active not recruiting |
| LX7101 (0.125%) | Primary Open-angle Glaucoma | Phase 1/2 · NCT01528111 | Completed |
| Treatment C Digoxin + 400 mg LX4211… | Healthy | Phase 1 · NCT02300350 | Completed |
| Treatment C (rosuvastatin + 400 mg LX4211… | Healthy | Phase 1 · NCT02300363 | Completed |
| Treatment B LX4211 | Healthy | Phase 1 · NCT02300350 | Completed |
| Treatment B (LX4211) | Healthy | Phase 1 · NCT02300363 | Completed |
| Treatment A digoxin | Healthy | Phase 1 · NCT02300350 | Completed |
| Treatment A (rosuvastatin) | Healthy | Phase 1 · NCT02300363 | Completed |
Also used in these trials (approved or third-party drugs, not LXRX's own candidates): Empagliflozin, Glimepiride, Insulin Glargine, Telotristat Ethyl, Gemcitabine Hydrochloride, Octreotide Acetate, Midazolam Hydrochloride, Famotidine, Omeprazole, Apixaban.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LXRX holds $183.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.6M/quarter from operations, an estimated runway of 63.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LXRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Participations S.a r.l. Artal Director, 10% owner |
Insider | 175,156,062 | 39.34% | 2026-04-30 |
| FMR LLC | Institution (13G, 5%+) | 66,743,390 | 14.99% | 2026-09-30 |
| Raymond Debbane Director · +43,478 options |
Insider | 51,750,221 | 11.62% | 2026-06-03 |
| Avicenna Life Sci Master Fund LP Director, 10% owner |
Insider | 1,538,462 | 0.35% | 2026-02-02 |
| Invus Global Management, LLC Director, 10% owner |
Insider | 1,385,689 | 0.31% | 2026-02-02 |
| Brian T Crum SVP, General Counsel & Secr. · +789,887 options |
Insider | 428,802 | 0.10% | 2026-02-28 |
| Philippe Amouyal Director · +43,478 options |
Insider | 374,486 | 0.08% | 2026-06-03 |
| Michael Exton Chief Executive Officer, Director · +2.30M options |
Insider | 328,496 | 0.07% | 2026-11-06 |
| Craig B Granowitz SVP, Chief Medical Officer · +924,440 options |
Insider | 323,430 | 0.07% | 2026-02-28 |
| Christopher J Sobecki Director · +43,478 options |
Insider | 293,177 | 0.07% | 2026-06-03 |
| Wendy McDermott SVP, Human Resources · +664,087 options |
Insider | 277,945 | 0.06% | 2026-02-28 |
| Sam L Barker Director · +43,478 options |
Insider | 213,771 | 0.05% | 2026-06-03 |
Share count 445,234,571 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LXRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →